trending Market Intelligence /marketintelligence/en/news-insights/trending/9esyin6tnfieckkaabdyzq2 content esgSubNav
In This List

MannKind names chief medical officer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


MannKind names chief medical officer

David Kendall will become MannKind Corp.'s chief medical officer Feb. 12.

Kendall, who has over three decades of experience, will replace Raymond Urbanski, who stepped down in September 2017 to pursue an opportunity elsewhere.

Kendall was most recently the vice president and research physician of Lilly Diabetes, a unit of Eli Lilly and Co.

At MannKind, he will assume full responsibility for leading scientific research, clinical development, regulatory and medical affairs activity.

Westlake Village, Calif.-based MannKind is focused on the development of treatments for diabetes and pulmonary arterial hypertension.